Moderna Inc (MRNA)vsMerus BV (MRUS)
MRNA
Moderna Inc
$143.97
+5.38%
HEALTHCARE · Cap: $56.02B
MRUS
Merus BV
$90.00
0.00%
HEALTHCARE · Cap: $6.83B
Smart Verdict
WallStSmart Research — data-driven comparison
Moderna Inc generates 3836% more annual revenue ($2.23B vs $56.61M). MRUS leads profitability with a 0.0% profit margin vs -141.4%. MRUS earns a higher WallStSmart Score of 24/100 (F).
MRNA
Avoid21
out of 100
Grade: F
MRUS
Avoid24
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+70.0%
Fair Value
$134.97
Current Price
$143.97
$9.00 discount
Intrinsic value data unavailable for MRUS.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Conservative balance sheet, low leverage
No standout strengths identified
Areas to Watch
Trading at 8.5x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
Trading at 8.8x book value
0.0% revenue growth
0.0% earnings growth
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bull Case : MRUS
MRUS has a balanced fundamental profile.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Bear Case : MRUS
The primary concerns for MRUS are Price/Book, Revenue Growth, EPS Growth.
Key Dynamics to Monitor
MRNA profiles as a turnaround stock while MRUS is a value play — different risk/reward profiles.
MRNA carries more volatility with a beta of 1.11 — expect wider price swings.
MRNA is growing revenue faster at 2.1% — sustainability is the question.
MRUS generates stronger free cash flow (-85M), providing more financial flexibility.
Bottom Line
MRUS scores higher overall (24/100 vs 21/100). MRNA offers better value entry with a 70.0% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Merus BV
HEALTHCARE · BIOTECHNOLOGY · USA
Merus NV, a clinical-stage immuno-oncology company, is dedicated to the discovery and development of bispecific antibody therapies in the Netherlands. The company is headquartered in Utrecht, the Netherlands.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?